Medtronic PLC $MDT Shares Purchased by Cerity Partners LLC

Cerity Partners LLC grew its position in shares of Medtronic PLC (NYSE:MDT) by 15.3% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 701,904 shares of the medical technology company’s stock after purchasing an additional 92,968 shares during the period. Cerity Partners LLC owned approximately 0.05% of Medtronic worth $66,849,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. AXQ Capital LP grew its holdings in Medtronic by 25.6% during the 2nd quarter. AXQ Capital LP now owns 9,890 shares of the medical technology company’s stock worth $862,000 after acquiring an additional 2,013 shares in the last quarter. GC Wealth Management RIA LLC grew its holdings in shares of Medtronic by 20.6% during the second quarter. GC Wealth Management RIA LLC now owns 33,569 shares of the medical technology company’s stock worth $2,926,000 after purchasing an additional 5,734 shares during the last quarter. Merit Financial Group LLC grew its stake in Medtronic by 37.5% during the 2nd quarter. Merit Financial Group LLC now owns 57,035 shares of the medical technology company’s stock worth $4,972,000 after buying an additional 15,561 shares during the last quarter. Verdence Capital Advisors LLC increased its holdings in shares of Medtronic by 22.0% in the 2nd quarter. Verdence Capital Advisors LLC now owns 29,396 shares of the medical technology company’s stock valued at $2,562,000 after acquiring an additional 5,296 shares during the period. Finally, World Investment Advisors increased its stake in Medtronic by 1.9% in the second quarter. World Investment Advisors now owns 156,107 shares of the medical technology company’s stock valued at $13,608,000 after purchasing an additional 2,868 shares during the period. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on MDT shares. Barclays upped their price target on Medtronic from $109.00 to $111.00 and gave the stock an “overweight” rating in a research note on Thursday, November 20th. Robert W. Baird set a $103.00 price target on Medtronic in a research note on Tuesday, December 16th. UBS Group increased their price objective on shares of Medtronic from $95.00 to $102.00 and gave the company a “neutral” rating in a research note on Wednesday, November 19th. Citigroup raised their price target on Medtronic from $101.00 to $112.00 and gave the stock a “buy” rating in a research report on Tuesday, October 7th. Finally, Morgan Stanley upped their price objective on Medtronic from $107.00 to $117.00 and gave the company an “overweight” rating in a research report on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eleven have given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $109.94.

Medtronic Stock Down 0.6%

Shares of NYSE MDT opened at $99.76 on Thursday. The stock has a market capitalization of $127.89 billion, a PE ratio of 26.89, a P/E/G ratio of 2.64 and a beta of 0.71. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57. The firm has a fifty day moving average of $98.02 and a 200-day moving average of $94.34. Medtronic PLC has a 52-week low of $79.55 and a 52-week high of $106.33.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.31 by $0.05. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The business had revenue of $8.96 billion for the quarter, compared to analyst estimates of $8.86 billion. During the same period last year, the company posted $1.26 EPS. The business’s quarterly revenue was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, analysts anticipate that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, January 16th. Stockholders of record on Friday, December 26th will be issued a dividend of $0.71 per share. The ex-dividend date is Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.8%. Medtronic’s payout ratio is presently 76.55%.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).